Sarepta Therapeutics Q3 revenue beats estimates on strong show from gene therapy ELEVIDYS

Sarepta Therapeutics

03/11/2025 21:33

Overview

Sarepta Q3 revenue of $399.4 mln beats analyst expectations

Adjusted EPS for Q3 beats consensus, indicating better-than-expected performance

Company completed ESSENCE study, showing positive trends despite not meeting primary endpoint

Outlook

Sarepta plans to meet FDA for traditional approval of AMONDYS 45 and VYONDYS 53

Regulatory discussions for ELEVIDYS safety labeling expected to conclude soon

Readouts for FSHD and DM1 studies expected in early 2026

Result Drivers

ELEVIDYS PERFORMANCE - Solid performance from gene therapy ELEVIDYS contributed significantly to revenue

FINANCIAL STRENGTH - Refinancing and cost restructuring initiatives strengthened financial position, achieving positive cash flow

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$399.40 mln
$338.70 mln (22 Analysts)
Q3 Adjusted EPS
Beat
-$0.13
-$0.81 (19 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 8 "strong buy" or "buy", 16 "hold" and 5 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Sarepta Therapeutics Inc is $18.00, about 33.4% below its October 31 closing price of $24.01

Press Release: ID:nBw8Rhm9wa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)